A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia

Sleep Medicine

Volumn 10, Issue 3, 2009, Pages 319-328

  Taibi, Diana M ^a   Vitiello, Michael V ^b   Barsness, Suzanne ^b   Elmer, Gary W ^a   Anderson, Gail D ^a   Landis, Carol A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Alternative medicine; Complementary therapies; Insomnia; Phytotherapy; Sleep; Valerian; Women

Indexed keywords

PLACEBO; VALERIAN;

AGED; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INSOMNIA; PHASE 2 CLINICAL TRIAL; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SINGLE DRUG DOSE; SLEEP WAKING CYCLE; UNSPECIFIED SIDE EFFECT;

AGED; AGING; CROSS-OVER STUDIES; FEMALE; HUMANS; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PHYTOTHERAPY; PLACEBOS; PLANT EXTRACTS; POLYSOMNOGRAPHY; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT FAILURE; VALERIAN;

EID: 64449084355     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sleep.2008.02.001     Document Type: Article

References (57)

1. Foley D.J., Monjan A.A., Brown S.L., Simonsick E.M., Wallace R.B., and Blazer D.G. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep 18 6 (1995) 425-432
2. National Sleep Foundation. 2003 Sleep in America Poll. [Internet] 2003 [cited 2007 October 9]. Available from: http://www.kintera.org/atf/cf/F6BF2668-A1B4-4FE8-8D1A-A5D39340D9CB/2003SleepPollExecSumm.pdf.
3. Vitiello M.V., Larsen L.H., and Moe K.E. Age-related sleep change: gender and estrogen effects on the subjective-objective sleep quality relationships of healthy, noncomplaining older men and women. J Psychosom Res 56 5 (2004) 503-510
4. Floyd J.A., Medler S.M., Ager J.W., and Janisse J.J. Age-related changes in initiation and maintenance of sleep: a meta-analysis. Res Nurs Health 23 2 (2000) 106-117
5. Ohayon M.M. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6 2 (2002) 97-111
6. Cooke J.R., and Ancoli-Israel S. Sleep and its disorders in older adults. Psychiatr Clin North Am 29 4 (2006) 1077-1093
7. Ancoli-Israel S. Sleep and aging: prevalence of disturbed sleep and treatment considerations in older adults. J Clin Psychiatry 66 Suppl. 9 (2005) 24-30
8. Roberts R.E., Shema S.J., Kaplan G.A., and Strawbridge W.J. Sleep complaints and depression in an aging cohort: a prospective perspective. Am J Psychiatry 157 1 (2000) 81-88
9. Dew M.A., Hoch C.C., Buysse D.J., Monk T.H., Begley A.E., Houck P.R., et al. Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom Med 65 1 (2003) 63-73
10. Basu R., Dodge H., Stoehr G.P., and Ganguli M. Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am J Geriatr Psychiatry 11 2 (2003) 205-213
11. Aparasu R.R., Mort J.R., and Brandt H. Psychotropic prescription use by community-dwelling elderly in the United States. J Am Geriatr Soc 51 5 (2003) 671-677
12. Glass J., Lanctot K.L., Herrmann N., Sproule B.A., and Busto U.E. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331 7526 (2005) 1169
13. Wagner J., Wagner M.L., and Hening W.A. Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia. Ann Pharmacother 32 6 (1998) 680-691
14. 2003 National Sleep Disorders Research Plan. Sleep 2003;26(3):253-257.
15. Eisenberg D.M., Kessler R.C., Van Rompay M.I., Kaptchuk T.J., Wilkey S.A., Appel S., et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135 5 (2001) 344-351
16. Kessler R.C., Davis R.B., Foster D.F., Van Rompay M.I., Walters E.E., Wilkey S.A., et al. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann Intern Med 135 4 (2001) 262-268
17. Ni H., Simile C., and Hardy A.M. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 40 4 (2002) 353-358
18. Bliwise D.L., and Ansari F.P. Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey. Sleep 30 7 (2007) 881-884
19. Pearson N.J., Johnson L.L., and Nahin R.L. Insomnia, trouble sleeping, and complementary and alternative medicine: analysis of the 2002 National Health Interview Survey data. Arch Intern Med 166 16 (2006) 1775-1782
20. Cuellar N.G., Rogers A.E., and Hisghman V. Evidenced based research of complementary and alternative medicine (CAM) for sleep in the community dwelling older adult. Geriatr Nurs 28 1 (2007) 46-52
21. Houghton P.J. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51 5 (1999) 505-512
22. Cavadas C., Araujo I., Cotrim M.D., Amaral T., Cunha A.P., Macedo T., et al. In vitro study on the interaction of Valeriana officinalis L. extracts and their amino acids on GABAA receptor in rat brain. Arzneimittelforschung 45 7 (1995) 753-755
23. Santos M.S., Ferreira F., Cunha A.P., Carvalho A.P., and Macedo T. An aqueous extract of valerian influences the transport of GABA in synaptosomes. Planta Med 60 3 (1994) 278-279
24. Schumacher B., Scholle S., Holzl J., Khudeir N., Hess S., and Muller C.E. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J Nat Prod 65 10 (2002) 1479-1485
25. Marder M., Viola H., Wasowski C., Fernandez S., Medina J.H., and Paladini A.C. 6-Methylapigenin and hesperidin: new valeriana flavonoids with activity on the CNS. Pharmacol Biochem Behav 75 3 (2003) 537-545
26. Khom S., Baburin I., Timin E., Hohaus A., Trauner G., Kopp B., et al. Valerenic acid potentiates and inhibits GABA(A) receptors: molecular mechanism and subunit specificity. Neuropharmacology 53 1 (2007) 178-187
27. Jansen W. Double blind trial of a mixture of valerian extract with valepotriates. Therapiewoche 27 14 (1977) 2779-2786
28. Kamm Kohl A.V., Jansen W., and Brockmann P. Moderne Baldriantherapie gegen nervöse Störungen im Senium. Med Welt 35 (1984) 1450-1454
29. Schulz H., Stolz C., and Muller J. The effect of valerian extract on sleep polygraphy in poor sleepers: a pilot study. Pharmacopsychiatry 27 4 (1994) 147-151
30. Diaper A., and Hindmarch I. A double-blind, placebo-controlled investigation of the effects of two doses of a valerian preparation on the sleep, cognitive and psychomotor function of sleep-disturbed older adults. Phytother Res 18 10 (2004) 831-836
31. Backhaus J., Junghanns K., Broocks A., Riemann D., and Hohagen F. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res 53 3 (2002) 737-740
32. Buysse D.J., Reynolds III C.F., Monk T.H., Berman S.R., and Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28 2 (1989) 193-213
33. Morin C.M., Mimeault V., and Gagne A. Nonpharmacological treatment of late-life insomnia. J Psychosom Res 46 2 (1999) 103-116
34. American Psychological Association. Sleep disorders. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; 1994, p. 597-661.
35. Edinger J.D., Bonnet M.H., Bootzin R.R., Doghramji K., Dorsey C.M., Espie C.A., et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep 27 8 (2004) 1567-1596
36. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 3 (1975) 189-198
37. Spitzer R.L., Kroenke K., and Williams J.B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282 18 (1999) 1737-1744
38. Russo J., and Vitaliano P.P. Life events as correlates of burden in spouse caregivers of persons with Alzheimer's disease. Exp Aging Res 21 3 (1995) 273-294
39. Vitiello M.V., Moe K.E., and Prinz P.N. Sleep complaints cosegregate with illness in older adults: clinical research informed by and informing epidemiological studies of sleep. J Psychosom Res 53 1 (2002) 555-559
40. Rechtschaffen A., and Kales A. A manual of standardized terminology: techniques and scoring system for sleep stages in human subjects (1968), UCLA Service/Brain Research Institute, Los Angeles
41. Ancoli-Israel S., Cole R., Alessi C., Chambers M., Moorcroft W., and Pollak C.P. The role of actigraphy in the study of sleep and circadian rhythms. Sleep 26 3 (2003) 342-392
42. Lichstein K.L., Stone K.C., Donaldson J., Nau S.D., Soeffing J.P., Murray D., et al. Actigraphy validation with insomnia. Sleep 29 2 (2006) 232-239
43. Schulz V., Hansel R., and Tyler V.E. Rational phytotherapy: a physician's guide to herbal medicine (2001), Springer, New York
44. Moore M. Medicinal plants of the Pacific west (1993), Red Crane Books, Santa Fe
45. Taibi D.M., Bourguignon C., and Taylor A.G. The effects of valerian extract on sleep disturbances in persons with arthritis. Sleep 29 Suppl. (2006) A316
46. Vorbach E.U., Gortelmeyer R., and Bruning J. Therapie von Insomnien: Wirksamkeit und Veträglichkeit eines Baldrianpräparats. Psychopharmakotherapie 3 3 (1996) 109-115
47. Coxeter P.D., Schluter P.J., Eastwood H.L., Nikles C.J., and Glasziou P.P. Valerian does not appear to reduce symptoms for patients with chronic insomnia in general practice using a series of randomized n-of-1 trials. Complement Ther Med 11 4 (2003) 215-222
48. Morin C.M., Koetter U., Bastien C., Ware J.C., and Wooten V. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep 28 11 (2005) 1465-1471
49. Jacobs B.P., Bent S., Tice J.A., Blackwell T., and Cummings S.R. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine 84 4 (2005) 197-207
50. Brattstrom A. Scientific evidence for a fixed extract combination (Ze 91019) from valerian and hops traditionally used as a sleep-inducing aid. Wien Med Wochenschr 157 13-14 (2007) 367-370
51. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005;28(9):1049-57.
52. Taibi D.M., Landis C.A., Petry H., and Vitiello M.V. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 11 3 (2007) 209-230
53. Bent S., Padula A., Moore D., Patterson M., and Mehling W. Valerian for sleep: a systematic review and meta-analysis. Am J Med 119 12 (2006) 1005-1012
54. Kuhlmann J., Berger W., Podzuweit H., and Schmidt U. The influence of valerian treatment on 'reaction time, alertness and concentration' in volunteers. Pharmacopsychiatry 32 6 (1999) 235-241
55. Polo-Kantola P., Saaresranta T., and Polo O. Aetiology and treatment of sleep disturbances during perimenopause and postmenopause. CNS Drugs 15 6 (2001) 445-452
56. Anderson G.D., Elmer G.W., Kantor E.D., Templeton I.E., and Vitiello M.V. Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytother Res 19 9 (2005) 801-803
57. Morin C.M., Colecchi C., Stone J., Sood R., and Brink D. Behavioral and pharmacological therapies for late-life insomnia. A randomized controlled trial. JAMA 281 11 (1999) 991-999